Objective: To observe the clinical effects of endoscopic hemostasis combined with intravenous drip of large dose Rabeprazole in the treatment of peptic ulcer bleeding high-risk patients. Methods: 83 cases of peptic ulcer bleeding high-risk patients were randomly divided into observation group and control group, and each group had 43 patients. The patients in observation group were treated with endoscopic hemostasis combined with intravenous drip of large dose Rabeprazole, while the patients in control group were treated with endoscopic hemostasis combined with intravenous drip of large dose Esomeprazole. The hemostatic treatment effect, hemostatic time, rehemorrhage rate and adverse effects of patients in 2 groups were compared. Results: There was no statistical significance of total effective rate, rehemorrhage rate at 72h and adverse effects rate between observation group and control group (P>0.05). The median hemostatic time of observation group was 25.5h, which was obviously shorter than control group (P<0.05). Conclusions: The therapeutic effects of treating peptic ulcer bleeding high-risk patients with endoscopic hemostasis combined intravenous drip of large dose Rabeprazole is equal to endoscopic hemostasis combined intravenous drip of large dose Esomeprazole; and combined intravenous drip of large dose Rabeprazole can obviously shorten hemostatic time, so it is worthy of clinical expansion.